Business
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial
About this update from Nexalin Technology, Inc.
[{"type":"text","content":"HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its appointment as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment emphasizes Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders in Washington, D.C. \"We are honored to be named Industry Co-Chair of the National TBI Registry Coalition,\" said Mark White, CEO of Nexalin. \"This role reflects our dedication to improving the lives of those affected by traumatic brain injuries. With federal spending on TBI projected to increase significantly, we are committed to working closely with policymakers and stakeholders in Washington to advance meaningful solutions that address the needs of this underserved population.\" This leadership role complements Nexalin's ongoing initiatives, including a collaborative study with the University of California, San Diego (UCSD), and the San Diego Veterans Affairs (VA) to explore innovative treatments for veterans suffering from TBI. Furthermore, Nexalin has been actively engaging with key legislators across Congress to strengthen relationships with federal agencies, aiming to enhance TBI care and support. The Company anticipates sharing additional developments in the near future. About Nexalin Technology, Inc. Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/. Forward-looking st...